CB 002

Drug Profile

CB 002

Alternative Names: CB-002; GC enriched liposomal mitoxantrone - Ceronco Biosciences; Glucosylceramide enriched liposomal mitoxantrone - Ceronco Biosciences; Mitoxantrone liposomal - Ceronco Biosciences

Latest Information Update: 27 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ceronco Biosciences
  • Class Anthraquinones; Antineoplastics
  • Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Acute lymphoblastic leukaemia; Pancreatic cancer

Most Recent Events

  • 26 Oct 2016 Preclinical trials in Acute lymphoblastic leukaemia (In children, In infants, In adolescents) in Netherlands (unspecified route)
  • 26 Oct 2016 Preclinical trials in Pancreatic cancer in Netherlands (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top